• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

    10/31/24 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMY alert in real time by email

    Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth

    • Third Quarter Revenues were $11.9 Billion, increasing 8% (+10% Adjusting for Foreign Exchange)
    • Growth Portfolio Revenues were $5.8 Billion, increasing 18% (+20% Adjusting for Foreign Exchange)
    • GAAP EPS was $0.60 and Non-GAAP EPS was $1.80; Includes Net Impact of $(0.09) Per Share for GAAP EPS and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
    • Achieved U.S. Approval of Cobenfy, the First New Pharmacological Approach to Treat Schizophrenia in Decades
    • Raising 2024 Revenue Guidance to Approximately +5% (+6% Adjusting for Foreign Exchange), Non-GAAP EPS Range Increased to $0.75 to $0.95

    Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2024.

    "We made important strides in the third quarter with the landmark U.S. approval of Cobenfy in schizophrenia, continued sales momentum, strong cash flow generation and key pipeline achievements," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "We're focused on closing out the year with strong execution as we deliver on our Growth Portfolio, prioritize high-growth opportunities and continue delivering transformational results for patients."

     

    Third Quarter

    $ in millions, except per share amounts

    2024

     

    2023

     

    Change

     

    Change Excl.

    F/X**

    Total Revenues

    $11,892

     

     

    $10,966

     

     

    8%

     

    10%

    Earnings Per Share — GAAP*

    0.60

     

     

    0.93

     

     

    (35)%

     

    N/A

    Earnings Per Share — Non-GAAP* **

    1.80

     

     

    2.00

     

     

    (10)%

     

    N/A

    Acquired IPRD Charge and Licensing Income Net Impact on Earnings Per Share

    (0.09

    )

     

    (0.03

    )

     

    N/A

     

    N/A

    *GAAP and Non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income.

    **See "Use of Non-GAAP Financial Information".

    THIRD QUARTER RESULTS

    All comparisons are made versus the same period in 2023 unless otherwise stated.

    • Bristol Myers Squibb posted third quarter revenues of $11.9 billion, an increase of 8%, or 10% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and Eliquis, partially offset by generic erosion of Sprycel due to the loss of exclusivity.
    • U.S. revenues increased 9% to $8.2 billion, and International revenues increased 7% to $3.7 billion, primarily due to the Growth Portfolio and higher demand for Eliquis, partially offset by generic erosion of Sprycel due to the loss of exclusivity. The negative impact from foreign exchange on International revenues was 4%.
    • On a GAAP basis, gross margin decreased from 77.1% to 75.1%, and on a non-GAAP basis decreased from 77.3% to 76.0%, primarily due to product mix.
    • On a GAAP and non-GAAP basis, marketing, selling and administrative expenses remained relatively flat at $2.0 billion.
    • On a GAAP basis, research and development expenses increased 6%, and 8% on a non-GAAP basis, to $2.4 billion, primarily due to recent acquisitions.
    • On a GAAP and non-GAAP basis, Acquired IPRD increased to $262 million from $80 million. On a GAAP and non-GAAP basis, licensing income was $25 million compared to $12 million.
    • On a GAAP basis, amortization of acquired intangible assets increased 7% to $2.4 billion, primarily due to the RayzeBio acquisition in 2024 and approval of Augtyro in the fourth quarter of 2023.
    • On a GAAP basis, the effective tax rate increased from 9.5% to 27.5%, and on a non-GAAP basis increased from 11.6% to 18.5%, primarily due to jurisdictional earnings mix and adjustments in 2023 to reflect IRS income tax guidance issued in 2023 regarding deductibility of certain non-U.S. research and development expenses.
    • On a GAAP basis, the company reported net income attributable to Bristol Myers Squibb of $1.2 billion, or $0.60 per share, during the third quarter of 2024 compared to $1.9 billion, or $0.93 per share, for the same period a year ago. The company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $3.7 billion, or $1.80 per share, during the third quarter of 2024 compared to $4.1 billion, or $2.00 per share, for the same period a year ago. In addition to the items above, GAAP and non-GAAP earnings per share were impacted by higher interest expense.
     

    THIRD QUARTER PRODUCT REVENUE HIGHLIGHTS

     

    ($ amounts in millions)

     

    Quarter Ended September

    30, 2024

     

    % Change from Quarter

    Ended September 30,

    2023

     

    % Change from

    Quarter Ended

    September 30,

    2023 Ex-F/X**

     

     

    U.S.

     

    Int'l (c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    Int'l(c)

     

    WW(d)

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

     

    $

    1,366

     

    $

    994

     

    $

    2,360

     

    2%

     

    7%

     

    4%

     

    16%

     

    7%

    Orencia

     

     

    706

     

     

    230

     

     

    936

     

    —%

     

    6%

     

    1%

     

    13%

     

    3%

    Yervoy

     

     

    399

     

     

    243

     

     

    642

     

    11%

     

    10%

     

    11%

     

    17%

     

    13%

    Reblozyl

     

     

    358

     

     

    89

     

     

    447

     

    79%

     

    85%

     

    80%

     

    90%

     

    81%

    Opdualag

     

     

    216

     

     

    17

     

     

    233

     

    33%

     

    >200%

     

    40%

     

    >200%

     

    40%

    Abecma

     

     

    77

     

     

    47

     

     

    124

     

    12%

     

    96%

     

    33%

     

    100%

     

    34%

    Zeposia

     

     

    105

     

     

    42

     

     

    147

     

    11%

     

    50%

     

    20%

     

    46%

     

    19%

    Breyanzi

     

     

    173

     

     

    51

     

     

    224

     

    125%

     

    >200%

     

    143%

     

    >200%

     

    143%

    Camzyos

     

     

    135

     

     

    21

     

     

    156

     

    101%

     

    >200%

     

    129%

     

    >200%

     

    129%

    Sotyktu

     

     

    51

     

     

    15

     

     

    66

     

    (18)%

     

    >200%

     

    —%

     

    >200%

     

    —%

    Augtyro

     

     

    10

     

     

    —

     

     

    10

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Krazati

     

     

    32

     

     

    2

     

     

    34

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(a)

     

     

    172

     

     

    261

     

     

    433

     

    15%

     

    61%

     

    39%

     

    64%

     

    41%

    Total Growth Portfolio

     

     

    3,800

     

     

    2,012

     

     

    5,812

     

    15%

     

    22%

     

    18%

     

    29%

     

    20%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

     

     

    2,045

     

     

    957

     

     

    3,002

     

    15%

     

    3%

     

    11%

     

    2%

     

    11%

    Revlimid

     

     

    1,212

     

     

    200

     

     

    1,412

     

    —%

     

    (9)%

     

    (1)%

     

    (6)%

     

    (1)%

    Pomalyst/Imnovid

     

     

    697

     

     

    201

     

     

    898

     

    15%

     

    (24)%

     

    3%

     

    (24)%

     

    3%

    Sprycel

     

     

    225

     

     

    65

     

     

    290

     

    (44)%

     

    (45)%

     

    (44)%

     

    (42)%

     

    (43)%

    Abraxane

     

     

    151

     

     

    102

     

     

    253

     

    (15)%

     

    24%

     

    (3)%

     

    37%

     

    1%

    Other Legacy Products(b)

     

     

    102

     

     

    123

     

     

    225

     

    17%

     

    (18)%

     

    (5)%

     

    (19)%

     

    (5)%

    Total Legacy Portfolio

     

     

    4,432

     

     

    1,648

     

     

    6,080

     

    4%

     

    (7)%

     

    1%

     

    (6)%

     

    1%

    Total Revenues

     

    $

    8,232

     

    $

    3,660

     

    $

    11,892

     

    9%

     

    7%

     

    8%

     

    11%

     

    10%

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Includes Nulojix, Onureg, Inrebic, Empliciti and royalty revenue.

    (b)

    Includes other mature brands.

    (c)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (d)

    Worldwide (WW) includes U.S. and International (Int'l).

    THIRD QUARTER PRODUCT REVENUE HIGHLIGHTS

    Growth Portfolio

    Growth Portfolio worldwide revenues increased to $5.8 billion compared to $4.9 billion in the prior year period, representing growth of 18% on a reported basis or 20% when adjusted for foreign exchange impacts. Growth Portfolio revenues were primarily driven by higher demand for Reblozyl, Breyanzi, Camzyos and Opdualag.

    Legacy Portfolio

    Revenues for the Legacy Portfolio in the third quarter were $6.1 billion compared to $6.0 billion in the prior year period, representing growth of 1% on a reported basis and when adjusted for foreign exchange impacts. Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, partially offset by a decline in demand for Sprycel due to generic erosion.

    PRODUCT AND PIPELINE UPDATE

    Bristol Myers Squibb recently achieved several important clinical and regulatory milestones, including the U.S. approval of Cobenfy and the disclosure of long-term cardiovascular and oncology data that underscore the strength of the company's science.

    With Cobenfy, the company is re-establishing its presence in neuroscience and introducing the first new pharmacological approach to treat schizophrenia in decades.

    Today, the company is providing an update on data from two Phase 3 oncology trials, CheckMate -8HW and CheckMate -901. Please see the table below for more information.

    Neuroscience

    Category

    Asset

    Milestone

    Regulatory

    CobenfyTM

    (xanomeline and

    trospium

    chloride)

    The U.S. Food and Drug Administration (FDA) approved Cobenfy, previously referred to as KarXT, for the treatment of schizophrenia in adults, with a mechanism of action distinct from current therapies. The approval is based on data from the EMERGENT clinical program, which includes three placebo-controlled efficacy and safety trials and two open-label trials evaluating the long-term safety and tolerability of Cobenfy for up to one year.

    Cardiovascular

    Category

    Asset

    Milestone

    Clinical &

    Research

    Camzyos®

    (mavacamten)

    Long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension study evaluating Camzyos in adult patients with New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy demonstrated that patients experienced consistent and sustained improvements in echocardiographic measures and biomarkers after up to 3.5 years of continuous treatment.

     

    Patients experienced an improvement in symptoms and functional capacity as measured by NYHA class and patient-reported outcomes. The safety profile of Camzyos for up to 3.5 years remained consistent with the established safety profile and no new safety signals were identified.

    Oncology

    Category

    Asset

    Milestone

    Regulatory

    Opdivo®

    (nivolumab)

    The FDA approved Opdivo for the treatment of adult patients with resectable (tumors ≥ 4cm or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery. The approval is based on results from the Phase 3 randomized CheckMate -77T trial.

     

    Opdivo +

    Yervoy®

    (ipilimumab)

    The FDA accepted the supplemental Biologics License Application for Opdivo plus Yervoy as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma. The acceptance is based on results from the Phase 3 CheckMate -9DW trial. The FDA assigned a Prescription Drug User Fee Act goal date of April 21, 2025.

    Clinical &

    Research

    Opdivo

    The Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to Opdivo monotherapy across all lines of therapy as a treatment for patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer met the dual primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review at a pre-specified interim analysis. Previously, Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy.

     

    Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in PFS compared to Opdivo monotherapy across all lines of therapy. The study is ongoing to assess various secondary endpoints, including overall survival (OS). The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data, with no new safety signals identified.

     

    Opdivo

    The Phase 3 CheckMate -901 trial evaluating Opdivo plus Yervoy versus standard-of-care non-cisplatin-based chemotherapy in patients with unresectable or metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy did not meet its primary endpoint of OS. The safety profile for Opdivo and Yervoy was consistent with previously reported data, with no new safety signals identified.

     

    Opdivo has previously shown clinical benefit across various stages of UC. These results do not impact those data or approved indications.

     

    nivolumab +

    relatlimab high

    dose

    The company announced plans to initiate a Phase 3 trial evaluating the fixed-dose combination of nivolumab and high-dose relatlimab plus chemotherapy as a first-line treatment for stage IV or recurrent non-squamous NSCLC with tumor cell PD-L1 expression of 1 to 49%. The decision was supported by findings from the Phase 2 RELATIVITY-104 trial.

     

    Opdivo +

    Yervoy

    10-year follow-up data from the Phase 3 CheckMate -067 trial showed continued durable improvement in survival with first-line Opdivo plus Yervoy therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untreated advanced or metastatic melanoma. With a minimum follow up of 10 years, median OS was 71.9 months with Opdivo plus Yervoy, the longest reported median OS in a Phase 3 advanced melanoma trial.

    Hematology

    Category

    Asset

    Milestone

    Regulatory

    Breyanzi®

    (lisocabtagene

    maraleucel)

    The European Medicines Agency (EMA) validated the Type II variation application to expand the indication for Breyanzi to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. The application is supported by data from the Phase 2 TRANSCEND FL study. Validation of the application confirms the submission is complete and begins the EMA's centralized review process.

     

    In addition, Japan's Ministry of Health, Labour and Welfare approved the supplemental New Drug Application for Breyanzi for the treatment of relapsed or refractory FL after one prior line of systemic therapy in patients with high-risk FL and after two or more lines of systemic therapy.

    Immunology

    Category

    Asset

    Milestone

    Clinical &

    Research

    Zeposia®

    (ozanimod)

    Data from the Phase 3 DAYBREAK trial demonstrated that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients treated with Zeposia for relapsing forms of multiple sclerosis.

     

    A separate DAYBREAK OLE safety analysis demonstrated declining or stable incidence rates of treatment-emergent adverse events, with relatively low rates of infections, serious infections and opportunistic infections over more than eight years of treatment with Zeposia.

    Financial Guidance

    Bristol Myers Squibb is raising its 2024 line-item guidance as noted below.

    2024 Line-Item Guidance

     

    Non-GAAP2

     

    July

    (Prior)

    October

    (Updated)

    Total Revenues

    Upper end of low single-

    digit range

    ~5% increase

    Total Revenues

    (excl. F/X)

    Upper end of low single-

    digit range

    ~6% increase

    Gross Margin %

    Between ~74% and ~75%

    Between ~74.5% and ~75%

    Operating Expenses1

    Low single-digit increase

    ~4% to ~5% increase

    Other income/(expense)

    ~($50M)

    ~$125M

    Effective tax rate

    ~66%

    ~60%

    Diluted EPS

    $0.60 - $0.90

    $0.75 - $0.95

    1 Operating Expenses = MS&A and R&D, excluding Acquired IPRD and Amortization of acquired intangible assets.

    2 See "Use of Non-GAAP Financial Information."

    The 2024 financial guidance excludes the impact of any potential future strategic acquisitions, divestitures, specified items that have not yet been identified and quantified, and the impact of future Acquired IPRD charges. To the extent we have quantified the impact of significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights, we may update this information from time to time on our website www.bms.com, in the "Investors" section. Non-GAAP guidance assumes current exchange rates. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

    A reconciliation of forward-looking non-GAAP measures, including non-GAAP EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. See "Cautionary Statement Regarding Forward-Looking Statements" and "Use of Non-GAAP Financial Information."

    Environmental, Social & Governance (ESG)

    As a leading biopharmaceutical company, Bristol Myers Squibb's passion for making an impact extends beyond the discovery, development and delivery of innovative medicines that help patients prevail over serious diseases. To learn more about our priorities and goals, please visit our latest ESG report.

    Conference Call Information

    Bristol Myers Squibb will host a conference call today, Thursday, October 31, 2024, at 8:00 a.m. ET, during which company executives will review quarterly financial results and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com.

    Investors and the public can register for the live conference call here. Those unable to register can access the live conference call by dialing in the U.S. toll-free 1-833-816-1116 or international +1 412-317-0705. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call.

    A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. A replay of the conference call will be available beginning at 11:30 a.m. ET on October 31, 2024, through 11:30 a.m. ET on November 14, 2024, by dialing in the U.S. toll free 1-877-344-7529 or international +1 412-317-0088, confirmation code: 9624003.

    About Bristol Myers Squibb

    Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.

    corporatefinancial-news

    Use of Non-GAAP Financial Information

    In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the company's financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company's baseline performance, supplement or enhance management's, analysts' and investors' overall understanding of the company's underlying financial performance and trends and facilitate comparisons among current, past and future periods. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items, as a percentage of revenues, non-GAAP operating margin, which is gross profit less marketing, selling and administrative expenses and research and development expenses excluding certain specified items as a percentage of revenues, non-GAAP operating expenses, which is marketing, selling and administrative and research and development expenses excluding certain specified items, non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expenses excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results.

    This earnings release and the accompanying tables also provide certain revenues and expenses, as well as non-GAAP measures, excluding the impact of foreign exchange ("Ex-Fx"). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-Fx financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.

    Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the company's business nor reflect the company's underlying business performance. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwinding of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, costs of acquiring a priority review voucher, divestiture gains or losses, stock compensation resulting from acquisition-related equity awards, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments), income resulting from the change in control of the Nimbus Therapeutics TYK2 Program and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Certain other significant tax items are also excluded such as the impact resulting from a non-U.S. tax ruling regarding the deductibility of a statutory impairment of subsidiary investments and release of income tax reserves relating to the Celgene acquisition.

    Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

    Reconciliations of the non-GAAP financial measures to the most comparable GAAP measures are provided in the accompanying financial tables and will also be available on the company's website at www.bms.com. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

    A reconciliation of forward-looking non-GAAP measures, including non-GAAP EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results.

    Website Information

    We routinely post important information for investors on our website, BMS.com, in the "Investors" section. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, Securities and Exchange Commission ("SEC") filings, public conference calls, presentations and webcasts. We may also use social media channels to communicate with our investors and the public about our company, our products and other matters, and those communications could be deemed to be material information. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document.

    Cautionary Statement Regarding Forward-Looking Statements

    This earnings release and the related attachments (as well as the oral statements made with respect to information contained in this release and the attachments) contain certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the company's 2024 financial guidance, plans and strategy, including its business development and capital allocation strategy, ESG priorities and goals, anticipated developments in the company's pipeline, expectations with respect to the company's future market position and the projected benefits of the company's alliances and other business development activities. These statements may be identified by the fact that they use words such as "should," "could," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe," "will" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. No forward-looking statement can be guaranteed and there is no assurance that the company will achieve its financial guidance and long-term targets, that the company's future clinical studies will support the data described in this release, that the company's product candidates will receive necessary clinical and manufacturing regulatory approvals, that the company's pipeline products will prove to be commercially successful, that clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes, or that contractual milestones will be achieved.

    Forward-looking statements are based on current expectations and projections about the company's future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond the company's control and could cause the company's future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; market actions taken by private and government payers to manage drug utilization and contain costs; the company's ability to retain patent exclusivity of certain products; regulatory changes that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; the company's ability to obtain and maintain regulatory approval for its product candidates; the company's ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; increasing industry competition; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the company's ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; failure to complete, or delays in completing, collaborations, acquisitions, divestitures, alliances and other portfolio actions and the failure to achieve anticipated benefits from such transactions and actions; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions or investigations; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the company's suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; the impact of counterfeit or unregistered versions of the company's products and from stolen products; product label changes or other measures that could reduce the market acceptance for the company's products and result in declining sales; safety or efficacy concerns regarding the company's products or any product in the same class as the company's products; the risk of cyber-attacks on the company's information systems or products and unauthorized disclosure of trade secrets or other confidential data; the company's ability to execute its financial, strategic and operational plans; the company's dependency on several key products; any decline in the company's future royalty streams; the company's ability to attract and retain key personnel; the impact of the company's significant indebtedness; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; risks relating to the use of social media platforms; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders' ability to obtain a judicial forum that they find favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics.

    Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the company's business and market, particularly those identified in the cautionary statement and risk factors discussion in the company's Annual Report on Form 10-K for the year ended December 31, 2023, as updated by the company's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

    BRISTOL-MYERS SQUIBB COMPANY

    CONSOLIDATED STATEMENTS OF EARNINGS

    (Unaudited, dollars and shares in millions except per share data)

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

     

     

     

     

     

     

     

    Net product sales

    $

    11,483

     

     

    $

    10,645

     

     

    $

    34,967

     

     

    $

    32,610

     

    Alliance and other revenues

     

    409

     

     

     

    321

     

     

     

    991

     

     

     

    919

     

    Total Revenues

     

    11,892

     

     

     

    10,966

     

     

     

    35,958

     

     

     

    33,529

     

     

     

     

     

     

     

     

     

    Cost of products sold(a)

     

    2,957

     

     

     

    2,506

     

     

     

    9,156

     

     

     

    7,948

     

    Marketing, selling and administrative

     

    1,983

     

     

     

    2,003

     

     

     

    6,278

     

     

     

    5,699

     

    Research and development

     

    2,374

     

     

     

    2,242

     

     

     

    7,968

     

     

     

    6,821

     

    Acquired IPRD

     

    262

     

     

     

    80

     

     

     

    13,343

     

     

     

    313

     

    Amortization of acquired intangible assets

     

    2,406

     

     

     

    2,256

     

     

     

    7,179

     

     

     

    6,769

     

    Other (income)/expense, net

     

    234

     

     

     

    (258

    )

     

     

    588

     

     

     

    (787

    )

    Total Expenses

     

    10,216

     

     

     

    8,829

     

     

     

    44,512

     

     

     

    26,763

     

     

     

     

     

     

     

     

     

    (Loss)/Earnings Before Income Taxes

     

    1,676

     

     

     

    2,137

     

     

     

    (8,554

    )

     

     

    6,766

     

    Provision for Income Taxes

     

    461

     

     

     

    203

     

     

     

    455

     

     

     

    488

     

    Net (Loss)/Earnings

     

    1,215

     

     

     

    1,934

     

     

     

    (9,009

    )

     

     

    6,278

     

    Noncontrolling Interest

     

    4

     

     

     

    6

     

     

     

    11

     

     

     

    15

     

    Net (Loss)/Earnings Attributable to BMS

    $

    1,211

     

     

    $

    1,928

     

     

    $

    (9,020

    )

     

    $

    6,263

     

     

     

     

     

     

     

     

     

    Weighted-Average Common Shares Outstanding:

     

     

     

     

     

     

     

    Basic

     

    2,028

     

     

     

    2,057

     

     

     

    2,026

     

     

     

    2,083

     

    Diluted

     

    2,031

     

     

     

    2,064

     

     

     

    2,026

     

     

     

    2,093

     

     

     

     

     

     

     

     

     

    (Loss)/Earnings per Common Share:

     

     

     

     

     

     

     

    Basic

    $

    0.60

     

     

    $

    0.94

     

     

    $

    (4.45

    )

     

    $

    3.01

     

    Diluted

     

    0.60

     

     

     

    0.93

     

     

     

    (4.45

    )

     

     

    2.99

     

     

     

     

     

     

     

     

     

    Other (income)/expense, net

     

     

     

     

     

     

     

    Interest expense(b)

    $

    505

     

     

    $

    280

     

     

    $

    1,451

     

     

    $

    850

     

    Royalty and licensing income

     

    (180

    )

     

     

    (365

    )

     

     

    (532

    )

     

     

    (1,068

    )

    Royalty income - divestitures

     

    (284

    )

     

     

    (217

    )

     

     

    (820

    )

     

     

    (623

    )

    Equity investment (gains)/losses

     

    (12

    )

     

     

    —

     

     

     

    (221

    )

     

     

    213

     

    Integration expenses

     

    69

     

     

     

    54

     

     

     

    214

     

     

     

    180

     

    Intangible asset impairments

     

    47

     

     

     

    29

     

     

     

    47

     

     

     

    29

     

    Litigation and other settlements

     

    —

     

     

     

    (61

    )

     

     

    71

     

     

     

    (393

    )

    Investment income

     

    (94

    )

     

     

    (107

    )

     

     

    (364

    )

     

     

    (304

    )

    Provision for restructuring

     

    78

     

     

     

    141

     

     

     

    558

     

     

     

    321

     

    Acquisition expense

     

    —

     

     

     

    —

     

     

     

    50

     

     

     

    —

     

    Other

     

    105

     

     

     

    (12

    )

     

     

    134

     

     

     

    8

     

    Other (income)/expense, net

    $

    234

     

     

    $

    (258

    )

     

    $

    588

     

     

    $

    (787

    )

    (a) Excludes amortization of acquired intangible assets.

    (b) Includes amortization of purchase price adjustments to Celgene debt.

    BRISTOL-MYERS SQUIBB COMPANY

    PRODUCT REVENUES

    FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

    (Unaudited, dollars in millions)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Change vs. 2023

     

     

    2024

     

    2023

     

    GAAP

     

    Excl. F/X**

     

     

    U.S.

     

    Int'l (c)

     

    WW (d)

     

    U.S.

     

    Int'l (c)

     

    WW (d)

     

    U.S.

     

    Int'l (c)

     

    WW (d)

     

    U.S.

     

    Int'l (c)

     

    WW (d)

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

     

    $

    1,366

     

    $

    994

     

    $

    2,360

     

    $

    1,343

     

    $

    932

     

    $

    2,275

     

    2%

     

    7%

     

    4%

     

    2%

     

    16%

     

    7%

    Orencia

     

     

    706

     

     

    230

     

     

    936

     

     

    708

     

     

    217

     

     

    925

     

    —%

     

    6%

     

    1%

     

    —%

     

    13%

     

    3%

    Yervoy

     

     

    399

     

     

    243

     

     

    642

     

     

    359

     

     

    220

     

     

    579

     

    11%

     

    10%

     

    11%

     

    11%

     

    17%

     

    13%

    Reblozyl

     

     

    358

     

     

    89

     

     

    447

     

     

    200

     

     

    48

     

     

    248

     

    79%

     

    85%

     

    80%

     

    79%

     

    90%

     

    81%

    Opdualag

     

     

    216

     

     

    17

     

     

    233

     

     

    162

     

     

    4

     

     

    166

     

    33%

     

    >200%

     

    40%

     

    33%

     

    >200%

     

    40%

    Abecma

     

     

    77

     

     

    47

     

     

    124

     

     

    69

     

     

    24

     

     

    93

     

    12%

     

    96%

     

    33%

     

    12%

     

    100%

     

    34%

    Zeposia

     

     

    105

     

     

    42

     

     

    147

     

     

    95

     

     

    28

     

     

    123

     

    11%

     

    50%

     

    20%

     

    11%

     

    46%

     

    19%

    Breyanzi

     

     

    173

     

     

    51

     

     

    224

     

     

    77

     

     

    15

     

     

    92

     

    125%

     

    >200%

     

    143%

     

    125%

     

    >200%

     

    143%

    Camzyos

     

     

    135

     

     

    21

     

     

    156

     

     

    67

     

     

    1

     

     

    68

     

    101%

     

    >200%

     

    129%

     

    101%

     

    >200%

     

    129%

    Sotyktu

     

     

    51

     

     

    15

     

     

    66

     

     

    62

     

     

    4

     

     

    66

     

    (18)%

     

    >200%

     

    —%

     

    (18)%

     

    >200%

     

    —%

    Augtyro

     

     

    10

     

     

    —

     

     

    10

     

     

    —

     

     

    —

     

     

    —

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Krazati

     

     

    32

     

     

    2

     

     

    34

     

     

    —

     

     

    —

     

     

    —

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(a)

     

     

    172

     

     

    261

     

     

    433

     

     

    149

     

     

    162

     

     

    311

     

    15%

     

    61%

     

    39%

     

    15%

     

    64%

     

    41%

    Total Growth Portfolio

     

     

    3,800

     

     

    2,012

     

     

    5,812

     

     

    3,291

     

     

    1,655

     

     

    4,946

     

    15%

     

    22%

     

    18%

     

    15%

     

    29%

     

    20%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

     

     

    2,045

     

     

    957

     

     

    3,002

     

     

    1,772

     

     

    933

     

     

    2,705

     

    15%

     

    3%

     

    11%

     

    15%

     

    2%

     

    11%

    Revlimid

     

     

    1,212

     

     

    200

     

     

    1,412

     

     

    1,209

     

     

    220

     

     

    1,429

     

    —%

     

    (9)%

     

    (1)%

     

    —%

     

    (6)%

     

    (1)%

    Pomalyst/Imnovid

     

     

    697

     

     

    201

     

     

    898

     

     

    606

     

     

    266

     

     

    872

     

    15%

     

    (24)%

     

    3%

     

    15%

     

    (24)%

     

    3%

    Sprycel

     

     

    225

     

     

    65

     

     

    290

     

     

    399

     

     

    118

     

     

    517

     

    (44)%

     

    (45)%

     

    (44)%

     

    (44)%

     

    (42)%

     

    (43)%

    Abraxane

     

     

    151

     

     

    102

     

     

    253

     

     

    178

     

     

    82

     

     

    260

     

    (15)%

     

    24%

     

    (3)%

     

    (15)%

     

    37%

     

    1%

    Other Legacy Products(b)

     

     

    102

     

     

    123

     

     

    225

     

     

    87

     

     

    150

     

     

    237

     

    17%

     

    (18)%

     

    (5)%

     

    17%

     

    (19)%

     

    (5)%

    Total Legacy Portfolio

     

     

    4,432

     

     

    1,648

     

     

    6,080

     

     

    4,251

     

     

    1,769

     

     

    6,020

     

    4%

     

    (7)%

     

    1%

     

    4%

     

    (6)%

     

    1%

    Total Revenues

     

    $

    8,232

     

    $

    3,660

     

    $

    11,892

     

    $

    7,542

     

    $

    3,424

     

    $

    10,966

     

    9%

     

    7%

     

    8%

     

    9%

     

    11%

     

    10%

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.

    (b)

    Includes other mature brands.

    (c)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (d)

    Worldwide (WW) includes U.S. and International (Int'l).

    BRISTOL-MYERS SQUIBB COMPANY

    PRODUCT REVENUES

    FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

    (Unaudited, dollars in millions)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Change vs. 2023

     

     

    2024

     

    2023

     

    GAAP

     

    Excl. F/X**

     

     

    U.S.

     

    Int'l (c)

     

    WW (d)

     

    U.S.

     

    Int'l (c)

     

    WW (d)

     

    U.S.

     

    Int'l (c)

     

    WW (d)

     

    U.S.

     

    Int'l (c)

     

    WW (d)

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

     

    $

    3,927

     

    $

    2,898

     

    $

    6,825

     

    $

    3,845

     

    $

    2,777

     

    $

    6,622

     

    2%

     

    4%

     

    3%

     

    2%

     

    14%

     

    7%

    Orencia

     

     

    2,020

     

     

    662

     

     

    2,682

     

     

    1,954

     

     

    662

     

     

    2,616

     

    3%

     

    —%

     

    3%

     

    3%

     

    8%

     

    5%

    Yervoy

     

     

    1,171

     

     

    684

     

     

    1,855

     

     

    1,039

     

     

    633

     

     

    1,672

     

    13%

     

    8%

     

    11%

     

    13%

     

    15%

     

    14%

    Reblozyl

     

     

    999

     

     

    227

     

     

    1,226

     

     

    534

     

     

    154

     

     

    688

     

    87%

     

    47%

     

    78%

     

    87%

     

    50%

     

    79%

    Opdualag

     

     

    637

     

     

    37

     

     

    674

     

     

    429

     

     

    8

     

     

    437

     

    48%

     

    >200%

     

    54%

     

    48%

     

    >200%

     

    54%

    Abecma

     

     

    183

     

     

    118

     

     

    301

     

     

    302

     

     

    70

     

     

    372

     

    (39)%

     

    69%

     

    (19)%

     

    (39)%

     

    74%

     

    (18)%

    Zeposia

     

     

    288

     

     

    120

     

     

    408

     

     

    219

     

     

    82

     

     

    301

     

    32%

     

    46%

     

    36%

     

    32%

     

    45%

     

    35%

    Breyanzi

     

     

    382

     

     

    102

     

     

    484

     

     

    218

     

     

    45

     

     

    263

     

    75%

     

    127%

     

    84%

     

    75%

     

    131%

     

    85%

    Camzyos

     

     

    342

     

     

    37

     

     

    379

     

     

    142

     

     

    1

     

     

    143

     

    141%

     

    >200%

     

    165%

     

    141%

     

    >200%

     

    165%

    Sotyktu

     

     

    126

     

     

    37

     

     

    163

     

     

    101

     

     

    6

     

     

    107

     

    25%

     

    >200%

     

    52%

     

    25%

     

    >200%

     

    54%

    Augtyro

     

     

    23

     

     

    —

     

     

    23

     

     

    —

     

     

    —

     

     

    —

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Krazati

     

     

    82

     

     

    5

     

     

    87

     

     

    —

     

     

    —

     

     

    —

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(a)

     

     

    488

     

     

    605

     

     

    1,093

     

     

    455

     

     

    431

     

     

    886

     

    7%

     

    40%

     

    23%

     

    7%

     

    44%

     

    25%

    Total Growth Portfolio

     

     

    10,668

     

     

    5,532

     

     

    16,200

     

     

    9,238

     

     

    4,869

     

     

    14,107

     

    15%

     

    14%

     

    15%

     

    15%

     

    22%

     

    18%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

     

     

    7,410

     

     

    2,728

     

     

    10,138

     

     

    6,610

     

     

    2,722

     

     

    9,332

     

    12%

     

    —%

     

    9%

     

    12%

     

    1%

     

    9%

    Revlimid

     

     

    3,830

     

     

    604

     

     

    4,434

     

     

    3,951

     

     

    696

     

     

    4,647

     

    (3)%

     

    (13)%

     

    (5)%

     

    (3)%

     

    (9)%

     

    (4)%

    Pomalyst/Imnovid

     

     

    2,010

     

     

    712

     

     

    2,722

     

     

    1,712

     

     

    839

     

     

    2,551

     

    17%

     

    (15)%

     

    7%

     

    17%

     

    (14)%

     

    7%

    Sprycel

     

     

    848

     

     

    240

     

     

    1,088

     

     

    1,011

     

     

    393

     

     

    1,404

     

    (16)%

     

    (39)%

     

    (23)%

     

    (16)%

     

    (35)%

     

    (21)%

    Abraxane

     

     

    450

     

     

    251

     

     

    701

     

     

    526

     

     

    231

     

     

    757

     

    (14)%

     

    9%

     

    (7)%

     

    (14)%

     

    24%

     

    (3)%

    Other Legacy Products(b)

     

     

    293

     

     

    382

     

     

    675

     

     

    250

     

     

    481

     

     

    731

     

    17%

     

    (21)%

     

    (8)%

     

    17%

     

    (19)%

     

    (6)%

    Total Legacy Portfolio

     

     

    14,841

     

     

    4,917

     

     

    19,758

     

     

    14,060

     

     

    5,362

     

     

    19,422

     

    6%

     

    (8)%

     

    2%

     

    6%

     

    (6)%

     

    2%

    Total Revenues

     

    $

    25,509

     

    $

    10,449

     

    $

    35,958

     

    $

    23,298

     

    $

    10,231

     

    $

    33,529

     

    9%

     

    2%

     

    7%

     

    9%

     

    7%

     

    9%

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.

    (b)

    Includes other mature brands.

    (c)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (d)

    Worldwide (WW) includes U.S. and International (Int'l).

    BRISTOL-MYERS SQUIBB COMPANY

    INTERNATIONAL REVENUES(a)

    FOREIGN EXCHANGE IMPACT (%)

    (Unaudited)

     

     

    Three Months Ended September 30, 2024

     

    Nine Months Ended September 30, 2024

     

    Revenue

    Change %

     

    F/X %

    Favorable/

    (Unfavorable)

    **

     

    Revenue

    Change % Ex-

    F/X **

     

    Revenue

    Change %

     

    F/X %

    Favorable/

    (Unfavorable)

    **

     

    Revenue

    Change % Ex-

    F/X **

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

    7%

     

    (9)%

     

    16%

     

    4%

     

    (10)%

     

    14%

    Orencia

    6%

     

    (7)%

     

    13%

     

    —%

     

    (8)%

     

    8%

    Yervoy

    10%

     

    (7)%

     

    17%

     

    8%

     

    (7)%

     

    15%

    Reblozyl

    85%

     

    (5)%

     

    90%

     

    47%

     

    (3)%

     

    50%

    Opdualag

    >200%

     

    NM

     

    >200%

     

    >200%

     

    NM

     

    >200%

    Abecma

    96%

     

    (4)%

     

    100%

     

    69%

     

    (5)%

     

    74%

    Zeposia

    50%

     

    4%

     

    46%

     

    46%

     

    1%

     

    45%

    Breyanzi

    >200%

     

    NM

     

    >200%

     

    127%

     

    (4)%

     

    131%

    Camzyos

    >200%

     

    NM

     

    >200%

     

    >200%

     

    NM

     

    >200%

    Sotyktu

    >200%

     

    NM

     

    >200%

     

    >200%

     

    NM

     

    >200%

    Augtyro

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Krazati

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(b)

    61%

     

    (3)%

     

    64%

     

    40%

     

    (4)%

     

    44%

    Total Growth Portfolio

    22%

     

    (7)%

     

    29%

     

    14%

     

    (8)%

     

    22%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

    3%

     

    1%

     

    2%

     

    —%

     

    (1)%

     

    1%

    Revlimid

    (9)%

     

    (3)%

     

    (6)%

     

    (13)%

     

    (4)%

     

    (9)%

    Pomalyst/Imnovid

    (24)%

     

    —%

     

    (24)%

     

    (15)%

     

    (1)%

     

    (14)%

    Sprycel

    (45)%

     

    (3)%

     

    (42)%

     

    (39)%

     

    (4)%

     

    (35)%

    Abraxane

    24%

     

    (13)%

     

    37%

     

    9%

     

    (15)%

     

    24%

    Other Legacy Products(c)

    (18)%

     

    1%

     

    (19)%

     

    (21)%

     

    (2)%

     

    (19)%

    Total Legacy Portfolio

    (7)%

     

    (1)%

     

    (6)%

     

    (8)%

     

    (2)%

     

    (6)%

    Total Revenues

    7%

     

    (4)%

     

    11%

     

    2%

     

    (5)%

     

    7%

    NM

    Not meaningful

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (b)

    Includes Onureg, Nulojix, Empliciti and royalty revenues.

    (c)

    Includes other mature brands.

    BRISTOL-MYERS SQUIBB COMPANY

    WORLDWIDE REVENUES(a)

    FOREIGN EXCHANGE IMPACT (%)

    (Unaudited)

     

     

    Three Months Ended September 30, 2024

     

    Nine Months Ended September 30, 2024

     

    Revenue

    Change %

     

    F/X %

    Favorable/

    (Unfavorable)

    **

     

    Revenue

    Change % Ex-

    F/X **

     

    Revenue

    Change %

     

    F/X %

    Favorable/

    (Unfavorable)

    **

     

    Revenue

    Change % Ex-

    F/X **

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

    4%

     

    (3)%

     

    7%

     

    3%

     

    (4)%

     

    7%

    Orencia

    1%

     

    (2)%

     

    3%

     

    3%

     

    (2)%

     

    5%

    Yervoy

    11%

     

    (2)%

     

    13%

     

    11%

     

    (3)%

     

    14%

    Reblozyl

    80%

     

    (1)%

     

    81%

     

    78%

     

    (1)%

     

    79%

    Opdualag

    40%

     

    —%

     

    40%

     

    54%

     

    —%

     

    54%

    Abecma

    33%

     

    (1)%

     

    34%

     

    (19)%

     

    (1)%

     

    (18)%

    Zeposia

    20%

     

    1%

     

    19%

     

    36%

     

    1%

     

    35%

    Breyanzi

    143%

     

    —%

     

    143%

     

    84%

     

    (1)%

     

    85%

    Camzyos

    129%

     

    —%

     

    129%

     

    165%

     

    —%

     

    165%

    Sotyktu

    —%

     

    —%

     

    —%

     

    52%

     

    (2)%

     

    54%

    Augtyro

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Krazati

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(b)

    39%

     

    (2)%

     

    41%

     

    23%

     

    (2)%

     

    25%

    Total Growth Portfolio

    18%

     

    (2)%

     

    20%

     

    15%

     

    (3)%

     

    18%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

    11%

     

    —%

     

    11%

     

    9%

     

    —%

     

    9%

    Revlimid

    (1)%

     

    —%

     

    (1)%

     

    (5)%

     

    (1)%

     

    (4)%

    Pomalyst/Imnovid

    3%

     

    —%

     

    3%

     

    7%

     

    —%

     

    7%

    Sprycel

    (44)%

     

    (1)%

     

    (43)%

     

    (23)%

     

    (2)%

     

    (21)%

    Abraxane

    (3)%

     

    (4)%

     

    1%

     

    (7)%

     

    (4)%

     

    (3)%

    Other Legacy Products(c)

    (5)%

     

    —%

     

    (5)%

     

    (8)%

     

    (2)%

     

    (6)%

    Total Legacy Portfolio

    1%

     

    —%

     

    1%

     

    2%

     

    —%

     

    2%

    Total Revenues

    8%

     

    (2)%

     

    10%

     

    7%

     

    (2)%

     

    9%

    **

     

    See "Use of Non-GAAP Financial Information".

    (a)

     

    Worldwide (WW) includes U.S. and International (Int'l).

    (b)

     

    Includes Onureg, Nulojix, Empliciti and royalty revenues.

    (c)

     

    Includes other mature brands.

    BRISTOL-MYERS SQUIBB COMPANY

    RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT *

    (Unaudited, dollars in millions)

     

    THREE MONTHS

    2024

     

    2023

     

    Change $

     

    Change %

     

    Favorable /

    (Unfavorable)

    F/X $ **

     

    2024

    Excl. F/X

    **

     

    Favorable /

    (Unfavorable)

    F/X % **

     

    % Change

    Excl. F/X

    **

    Revenues

    $

    11,892

     

     

    $

    10,966

     

     

    $

    926

     

     

    8%

     

    $

    (135)

     

    $

    12,027

     

    (2)%

     

    10%

    Gross profit

     

    8,935

     

     

     

    8,460

     

     

     

    475

     

     

    6%

     

     

    N/A

     

     

    N/A

     

    N/A

     

    N/A

    Gross profit excluding specified items(a)

     

    9,036

     

     

     

    8,476

     

     

     

    560

     

     

    7%

     

     

    N/A

     

     

    N/A

     

    N/A

     

    N/A

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin(b)

     

    75.1

    %

     

     

    77.1

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin excluding specified items

     

    76.0

    %

     

     

    77.3

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Marketing, selling and administrative

     

    1,983

     

     

     

    2,003

     

     

     

    (20

    )

     

    (1)%

     

     

    15

     

     

    1,998

     

    1%

     

    —%

    Marketing, selling and administrative excluding specified items(a)

     

    1,976

     

     

     

    1,938

     

     

     

    38

     

     

    2%

     

     

    15

     

     

    1,991

     

    1%

     

    3%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

    2,374

     

     

    2,242

     

     

     

    132

     

     

    6%

     

     

    8

     

     

    2,382

     

    —%

     

    6%

    Research and development excluding specified items(a)

     

    2,353

     

     

    2,178

     

     

     

    175

     

     

    8%

     

     

    8

     

     

    2,361

     

    —%

     

    8%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin(c)

     

    38.5

    %

     

     

    38.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin excluding specified items

     

    39.6

    %

     

     

    39.8

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    NINE MONTHS

    2024

     

    2023

     

    Change $

     

    Change %

     

    Favorable /

    (Unfavorable)

    F/X $ **

     

    2024

    Excl. F/X

    **

     

    Favorable /

    (Unfavorable)

    F/X % **

     

    % Change

    Excl. F/X

    **

    Revenues

    $

    35,958

     

     

    $

    33,529

     

     

    $

    2,429

     

     

    7%

     

    $

    (512)

     

    $

    36,470

     

    (2)%

     

    9%

    Gross profit

     

    26,802

     

     

     

    25,581

     

     

     

    1,221

     

     

    5%

     

     

    N/A

     

     

    N/A

     

    N/A

     

    N/A

    Gross profit excluding specified items(a)

     

    27,221

     

     

     

    25,718

     

     

     

    1,503

     

     

    6%

     

     

    N/A

     

     

    N/A

     

    N/A

     

    N/A

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin(b)

     

    74.5

    %

     

     

    76.3

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin excluding specified items

     

    75.7

    %

     

     

    76.7

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Marketing, selling and administrative

     

    6,278

     

     

     

    5,699

     

     

     

    579

     

     

    10%

     

     

    68

     

     

    6,346

     

    1%

     

    11%

    Marketing, selling and administrative excluding specified items(a)

     

    5,887

     

     

     

    5,614

     

     

     

    273

     

     

    5%

     

     

    68

     

     

    5,955

     

    1%

     

    6%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

    7,968

     

     

     

    6,821

     

     

     

    1,147

     

     

    17%

     

     

    32

     

     

    8,000

     

    —%

     

    17%

    Research and development excluding specified items(a)

     

    6,994

     

     

     

    6,636

     

     

     

    358

     

     

    5%

     

     

    32

     

     

    7,026

     

    1%

     

    6%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin(c)

     

    34.9

    %

     

     

    39.0

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin excluding specified items

     

    39.9

    %

     

     

    40.2

    %

     

     

     

     

     

     

     

     

     

     

     

     

    *

    Foreign exchange impacts were derived by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results.

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Refer to the Specified Items schedule below for further details.

    (b)

    Represents gross profit as a percentage of Revenues.

    (c)

    Operating margin represents gross profit less marketing, selling and administrative expenses and research and development expenses, as a percentage of Revenues.

    BRISTOL-MYERS SQUIBB COMPANY

    SPECIFIED ITEMS

    (Unaudited, dollars in millions)

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Inventory purchase price accounting adjustments

    $

    13

     

     

    $

    —

     

     

    $

    34

     

     

    $

    84

     

    Intangible asset impairment

     

    —

     

     

     

    —

     

     

     

    280

     

     

     

    —

     

    Site exit and other costs

     

    88

     

     

     

    16

     

     

     

    105

     

     

     

    53

     

    Cost of products sold

     

    101

     

     

     

    16

     

     

     

    419

     

     

     

    137

     

     

     

     

     

     

     

     

     

    Acquisition related charges(a)

     

    —

     

     

     

    —

     

     

     

    372

     

     

     

    —

     

    Site exit and other costs

     

    7

     

     

     

    65

     

     

     

    19

     

     

     

    85

     

    Marketing, selling and administrative

     

    7

     

     

     

    65

     

     

     

    391

     

     

     

    85

     

     

     

     

     

     

     

     

     

    IPRD impairments

     

    —

     

     

     

    60

     

     

     

    590

     

     

     

    80

     

    Priority review voucher

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    95

     

    Acquisition related charges(a)

     

    —

     

     

     

    —

     

     

     

    348

     

     

     

    —

     

    Site exit and other costs

     

    21

     

     

     

    4

     

     

     

    36

     

     

     

    10

     

    Research and development

     

    21

     

     

     

    64

     

     

     

    974

     

     

     

    185

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

    2,406

     

     

     

    2,256

     

     

     

    7,179

     

     

     

    6,769

     

     

     

     

     

     

     

     

     

    Interest expense(b)

     

    (12

    )

     

     

    (12

    )

     

     

    (37

    )

     

     

    (39

    )

    Equity investment (gain)/losses

     

    (13

    )

     

     

    (2

    )

     

     

    (222

    )

     

     

    206

     

    Acquisition expenses

     

    —

     

     

     

    —

     

     

     

    50

     

     

     

    —

     

    Integration expenses

     

    69

     

     

     

    54

     

     

     

    214

     

     

     

    180

     

    Litigation and other settlements

     

    —

     

     

     

    (62

    )

     

     

    61

     

     

     

    (397

    )

    Provision for restructuring

     

    78

     

     

     

    141

     

     

     

    558

     

     

     

    321

     

    Intangible asset impairment

     

    47

     

     

     

    29

     

     

     

    47

     

     

     

    29

     

    Other

     

    106

     

     

     

    (1

    )

     

     

    116

     

     

     

    (6

    )

    Other (income)/expense, net

     

    275

     

     

     

    147

     

     

     

    787

     

     

     

    294

     

     

     

     

     

     

     

     

     

    Increase to Earnings before income taxes

     

    2,810

     

     

     

    2,548

     

     

     

    9,750

     

     

     

    7,470

     

     

     

     

     

     

     

     

     

    Income taxes on items above

     

    (371

    )

     

     

    (340

    )

     

     

    (1,296

    )

     

     

    (944

    )

    Income tax reserve releases

     

    —

     

     

     

    —

     

     

     

    (502

    )

     

     

    —

     

    Income taxes attributed to a non-U.S. tax ruling

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (656

    )

    Income taxes

     

    (371

    )

     

     

    (340

    )

     

     

    (1,798

    )

     

     

    (1,600

    )

     

     

     

     

     

     

     

     

    Increase to net earnings

    $

    2,439

     

     

    $

    2,208

     

     

    $

    7,952

     

     

    $

    5,870

     

    (a)

    Includes cash settlement of unvested stock awards, and other related costs incurred in connection with the recent acquisitions of Karuna, RayzeBio and Mirati.

    (b)

    Includes amortization of purchase price adjustments to Celgene debt.

    BRISTOL-MYERS SQUIBB COMPANY

    RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS

    (Unaudited, dollars and shares in millions except per share data)

     

     

    Three Months Ended September 30,

    2024

     

    Nine Months Ended September 30,

    2024

     

    GAAP

     

    Specified

    Items(a)

     

    Non-GAAP

     

    GAAP

     

    Specified

    Items(a)

     

    Non-GAAP

    Gross profit

    $

    8,935

     

     

    $

    101

     

     

    $

    9,036

     

     

    $

    26,802

     

     

    $

    419

     

     

    $

    27,221

     

    Marketing, selling and administrative

     

    1,983

     

     

     

    (7

    )

     

     

    1,976

     

     

     

    6,278

     

     

     

    (391

    )

     

     

    5,887

     

    Research and development

     

    2,374

     

     

     

    (21

    )

     

     

    2,353

     

     

     

    7,968

     

     

     

    (974

    )

     

     

    6,994

     

    Amortization of acquired intangible assets

     

    2,406

     

     

     

    (2,406

    )

     

     

    —

     

     

     

    7,179

     

     

     

    (7,179

    )

     

     

    —

     

    Other (income)/expense, net

     

    234

     

     

     

    (275

    )

     

     

    (41

    )

     

     

    588

     

     

     

    (787

    )

     

     

    (199

    )

    Earnings/(Loss) before income taxes

     

    1,676

     

     

     

    2,810

     

     

     

    4,486

     

     

     

    (8,554

    )

     

     

    9,750

     

     

     

    1,196

     

    Provision for income taxes

     

    461

     

     

     

    371

     

     

     

    832

     

     

     

    455

     

     

     

    1,798

     

     

     

    2,253

     

    Net earnings/(loss) attributable to BMS used for diluted EPS calculation

    $

    1,211

     

     

    $

    2,439

     

     

    $

    3,650

     

     

    $

    (9,020

    )

     

    $

    7,952

     

     

    $

    (1,068

    )

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding—diluted

     

    2,031

     

     

     

    2,031

     

     

     

    2,031

     

     

     

    2,026

     

     

     

    2,026

     

     

     

    2,026

     

    Diluted earnings/(loss) per share

    $

    0.60

     

     

    $

    1.20

     

     

    $

    1.80

     

     

    $

    (4.45

    )

     

    $

    3.92

     

     

    $

    (0.53

    )

     

     

     

     

     

     

     

     

     

     

     

     

    Effective tax rate

     

    27.5

    %

     

     

    (9.0

    )%

     

     

    18.5

    %

     

     

    (5.3

    )%

     

     

    193.7

    %

     

     

    188.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended September 30,

    2023

     

    Nine Months Ended September 30,

    2023

     

    GAAP

     

    Specified

    Items(a)

     

    Non-GAAP

     

    GAAP

     

    Specified

    Items(a)

     

    Non-GAAP

    Gross profit

    $

    8,460

     

     

    $

    16

     

     

    $

    8,476

     

     

    $

    25,581

     

     

    $

    137

     

     

    $

    25,718

     

    Marketing, selling and administrative

     

    2,003

     

     

     

    (65

    )

     

     

    1,938

     

     

     

    5,699

     

     

     

    (85

    )

     

     

    5,614

     

    Research and development

     

    2,242

     

     

     

    (64

    )

     

     

    2,178

     

     

     

    6,821

     

     

     

    (185

    )

     

     

    6,636

     

    Amortization of acquired intangible assets

     

    2,256

     

     

     

    (2,256

    )

     

     

    —

     

     

     

    6,769

     

     

     

    (6,769

    )

     

     

    —

     

    Other (income)/expense, net

     

    (258

    )

     

     

    (147

    )

     

     

    (405

    )

     

     

    (787

    )

     

     

    (294

    )

     

     

    (1,081

    )

    Earnings before income taxes

     

    2,137

     

     

     

    2,548

     

     

     

    4,685

     

     

     

    6,766

     

     

     

    7,470

     

     

     

    14,236

     

    Provision for income taxes

     

    203

     

     

     

    340

     

     

     

    543

     

     

     

    488

     

     

     

    1,600

     

     

     

    2,088

     

    Net earnings attributable to BMS used for diluted EPS calculation

    $

    1,928

     

     

    $

    2,208

     

     

    $

    4,136

     

     

    $

    6,263

     

     

    $

    5,870

     

     

    $

    12,133

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding—diluted

     

    2,064

     

     

     

    2,064

     

     

     

    2,064

     

     

     

    2,093

     

     

     

    2,093

     

     

     

    2,093

     

    Diluted earnings per share

    $

    0.93

     

     

    $

    1.07

     

     

    $

    2.00

     

     

    $

    2.99

     

     

    $

    2.81

     

     

    $

    5.80

     

     

     

     

     

     

     

     

     

     

     

     

     

    Effective tax rate

     

    9.5

    %

     

     

    2.1

    %

     

     

    11.6

    %

     

     

    7.2

    %

     

     

    7.5

    %

     

     

    14.7

    %

    (a) Refer to the Specified Items schedule above for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

    BRISTOL-MYERS SQUIBB COMPANY

    NET DEBT CALCULATION

    AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023

    (Unaudited, dollars in millions)

     

     

    September 30,

    2024

     

    December 31,

    2023

     

     

     

     

    Cash and cash equivalents

    $

    7,890

     

     

    $

    11,464

     

    Marketable debt securities - current

     

    204

     

     

     

    816

     

    Marketable debt securities - non-current

     

    324

     

     

     

    364

     

    Cash, cash equivalents and marketable debt securities

    $

    8,418

     

     

    $

    12,644

     

    Short-term debt obligations

     

    (1,078

    )

     

     

    (3,119

    )

    Long-term debt

     

    (48,674

    )

     

     

    (36,653

    )

    Net debt position

    $

    (41,334

    )

     

    $

    (27,128

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241031512594/en/

    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY

    DatePrice TargetRatingAnalyst
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    4/22/2025Overweight
    Piper Sandler
    12/16/2024$70.00Hold → Buy
    Jefferies
    12/10/2024$63.00Neutral
    BofA Securities
    11/15/2024Peer Perform
    Wolfe Research
    11/13/2024Neutral → Outperform
    Daiwa Securities
    11/12/2024$73.00Market Perform → Outperform
    Leerink Partners
    10/25/2024$75.00 → $55.00Buy → Neutral
    Citigroup
    More analyst ratings

    $BMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

      Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score Treatment with Cobenfy and an atypical antipsychotic showed a numerical improvement compared to treatment with placebo and an atypical antipsychotic Cobenfy's safety and tolerability profile as an adjunctive therapy was consistent with previous monotherapy trials Bristol Myers Squibb (NYSE:BMY) today announced topline results from the Phase 3 ARISE trial evaluating the efficacy and

      4/22/25 4:15:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Chief Commercial Officer Lenkowsky Adam

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      5/5/25 5:41:48 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Glob. Prod. Dev. & Supply Shanahan Karin converted options into 3,306 shares and covered exercise/tax liability with 1,692 shares, increasing direct ownership by 13% to 13,797 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/3/25 5:15:32 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers upgraded by Jefferies with a new price target

      Jefferies upgraded Bristol-Myers from Hold to Buy and set a new price target of $70.00

      12/16/24 6:45:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    SEC Filings

    See more
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      5/7/25 5:04:09 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Bristol-Myers Squibb Company

      10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 11:45:34 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 7:11:41 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

      Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company wh

      3/13/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Announces Dividend

      Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2025, to stockholders of record at the close of business on April 4, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 2, 2025, to stockholders of record at the close of business on May 6, 2025. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and d

      3/3/25 4:16:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/21/25 7:09:34 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/19/25 7:19:54 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/23 11:12:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/22 3:33:30 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/10/21 10:39:37 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate